{
  "term": "Adalimumab",
  "role": "concept",
  "parent_concepts": [
    "Medicine"
  ],
  "layer": 5,
  "domain": "PhysicalWorld",
  "definition": "Adalimumab, is a\ndisease-modifying antirheumatic drug and monoclonal antibody that\nworks by inactivating tumor necrosis factor-alpha (TNF\u03b1). It is sold\nunder the brand name Humira, among others. It is a medication used to\ntreat rheumatoid arthritis, psoriatic arthritis, ankylosing\nspondylitis, &%CrohnsDisease, &%UlcerativeColitis, psoriasis,\nhidradenitis suppurativa, uveitis, and juvenile idiopathic &%Arthritis.\nUse is generally only recommended in people who have not responded to\nother treatments. It is administered by injection under the skin.\nCommon side effects include upper respiratory tract infections, pain\nat the site of injection, rash, and headache. Other side effects may\ninclude serious infections, cancer, anaphylaxis, reactivation of\nhepatitis B, multiple sclerosis, heart failure, liver failure, and\naplastic anemia. Use during pregnancy is not recommended, but some\nsources show use during breastfeeding may be safe.[from Wikipedia]",
  "definition_source": "SUMO",
  "aliases": [
    "adalimumab"
  ],
  "wordnet": {
    "synsets": [
      "adalimumab.n.01"
    ],
    "canonical_synset": "adalimumab.n.01",
    "lemmas": [
      "adalimumab"
    ],
    "pos": "noun"
  },
  "relationships": {
    "related": [],
    "antonyms": [],
    "has_part": [
      "Humira"
    ],
    "part_of": []
  },
  "safety_tags": {
    "risk_level": "low",
    "impacts": [],
    "treaty_relevant": false,
    "harness_relevant": false
  },
  "training_hints": {
    "positive_examples": [],
    "negative_examples": [],
    "disambiguation": "",
    "seed_terms": [
      "adalimumab"
    ]
  },
  "children": [
    "Humira"
  ],
  "is_category_lens": true,
  "child_count": 1
}